News
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable ...
Zacks Investment Research on MSN22h
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to NoteIn the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Today's Research Daily features new research reports on 16 major stocks, including SAP SE, Novo Nordisk A/S and Thermo Fisher Scientific Inc., as well a micro-cap stock FONAR Corp.
Zacks Investment Research on MSN7d
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on ItNovo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback